NO20001240L - Kay-A immunsystemprotein - Google Patents

Kay-A immunsystemprotein

Info

Publication number
NO20001240L
NO20001240L NO20001240A NO20001240A NO20001240L NO 20001240 L NO20001240 L NO 20001240L NO 20001240 A NO20001240 A NO 20001240A NO 20001240 A NO20001240 A NO 20001240A NO 20001240 L NO20001240 L NO 20001240L
Authority
NO
Norway
Prior art keywords
kay
immune system
system protein
tnf
ligands
Prior art date
Application number
NO20001240A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001240D0 (no
Inventor
Jurg Tschopp
Original Assignee
Apotech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotech Sa filed Critical Apotech Sa
Publication of NO20001240D0 publication Critical patent/NO20001240D0/no
Publication of NO20001240L publication Critical patent/NO20001240L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20001240A 1997-09-12 2000-03-09 Kay-A immunsystemprotein NO20001240L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
PCT/US1998/019037 WO1999012964A2 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein

Publications (2)

Publication Number Publication Date
NO20001240D0 NO20001240D0 (no) 2000-03-09
NO20001240L true NO20001240L (no) 2000-05-10

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001240A NO20001240L (no) 1997-09-12 2000-03-09 Kay-A immunsystemprotein

Country Status (17)

Country Link
EP (1) EP1012270A2 (de)
JP (1) JP2001515711A (de)
KR (1) KR20010023892A (de)
CN (1) CN1269832A (de)
AU (1) AU9315298A (de)
BR (1) BR9812433A (de)
CA (1) CA2303424A1 (de)
EA (1) EA200000311A1 (de)
EE (1) EE200000148A (de)
HU (1) HUP0004034A3 (de)
IL (1) IL134480A0 (de)
IS (1) IS5375A (de)
NO (1) NO20001240L (de)
PL (1) PL339740A1 (de)
SK (1) SK3532000A3 (de)
TR (1) TR200000654T2 (de)
WO (1) WO1999012964A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
WO1999026463A2 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
WO1999033980A2 (en) * 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
HUP0105283A3 (en) 1999-01-25 2004-08-30 Biogen Idec Ma Inc Cambridge Baff, inhibitors thereof and their use in the modulation of b-cell response
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
NZ513290A (en) * 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
WO2000068378A1 (en) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
EE05673B1 (et) * 1999-08-17 2013-08-15 Biogen, Inc. BAFF-retseptor (BCMA), immunoregulatoorne agens
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU3495301A (en) 2000-02-11 2001-08-20 Biogen Inc Heterologous polypeptide of the tnf family
DE60028830T2 (de) 2000-02-16 2007-01-18 Genentech, Inc., South San Francisco Anti-april antikörper und hybridomazellen
WO2001087979A2 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
KR101287395B1 (ko) 2000-06-16 2014-11-04 휴먼 게놈 사이언시즈, 인코포레이티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
AU2001288260A1 (en) * 2000-08-15 2002-03-13 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EP2292655B1 (de) 2001-05-11 2012-03-14 Amgen SF, LLC Peptide und damit zusammenhängende an Tall-1 bindende Moleküle
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
CA2520097C (en) 2003-03-28 2014-10-07 Biogen Idec Ma Inc. Truncated baff receptors
JP2007526220A (ja) 2003-06-05 2007-09-13 ジェネンテック・インコーポレーテッド Ｂ細胞疾患の併用療法
KR20070001880A (ko) 2003-10-20 2007-01-04 바이오겐 아이덱 엠에이 인코포레이티드 Ｂαｆｆ 길항제를 위한 치료 섭생법
EP1709072A1 (de) * 2004-01-29 2006-10-11 Genentech, Inc. Varianten der extrazellulären domäne von bcma und verwendungen dafür
EP1812060A2 (de) 2004-10-05 2007-08-01 Genentech, Inc. Verfahren zur behandlung von vaskulitis
CA2583900A1 (en) 2004-10-13 2006-04-27 The Washington University Use of baff to treat sepsis
AU2005318086B2 (en) 2004-12-23 2011-07-07 Merck Serono Sa BCMA polypeptides and uses thereof
EP1922079A2 (de) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Verfahren zur behandlung und prävention abnormaler zellproliferation mittels taci-fusionsmolekülen
KR20080056714A (ko) 2005-08-09 2008-06-23 지모제넥틱스, 인코포레이티드 ＴＡＣＩ―Ｉｇ 융합 분자를 사용하여 Ｂ―세포 악성종양을치료하는 방법
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
CN101489573B (zh) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
MX353186B (es) 2009-09-03 2018-01-05 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
EP2680884B1 (de) 2011-02-28 2018-01-17 F. Hoffmann-La Roche AG Biologische marker und verfahren zur vorhersage der reaktion auf b-zellen-antagonisten
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JP6577958B2 (ja) 2014-04-11 2019-09-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン誘導体およびＭＤＭ２−ｐ５３阻害剤としてのそれらの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0682705A1 (de) * 1993-02-03 1995-11-22 N.V. Innogenetics S.A. TNF - Alpha - Muteine und Verfahren zu deren Herstellung
AU6166396A (en) * 1995-06-07 1996-12-30 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical prepara tions
PT939804E (pt) * 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5

Also Published As

Publication number Publication date
EA200000311A1 (ru) 2000-10-30
EP1012270A2 (de) 2000-06-28
WO1999012964A3 (en) 1999-05-27
AU9315298A (en) 1999-03-29
CA2303424A1 (en) 1999-03-18
JP2001515711A (ja) 2001-09-25
BR9812433A (pt) 2000-09-26
NO20001240D0 (no) 2000-03-09
HUP0004034A2 (en) 2001-03-28
KR20010023892A (ko) 2001-03-26
EE200000148A (et) 2001-02-15
TR200000654T2 (tr) 2000-07-21
CN1269832A (zh) 2000-10-11
WO1999012964A2 (en) 1999-03-18
HUP0004034A3 (en) 2002-08-28
PL339740A1 (en) 2001-01-02
SK3532000A3 (en) 2001-12-03
IS5375A (is) 2000-02-11
IL134480A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
NO20001240L (no) Kay-A immunsystemprotein
NO20084906L (no) DNA-sekvens som koder for tumornekrosefaktorrelatert ligand (TRELL), vertsorganisme transformert med slikt DNA samt TRELL, fremstilling og anvendelse derav ved fremstilling av medikamenter og antistoffer
WO1999012965A3 (en) April- a novel protein with growth effects
DE69433406T2 (de) Antikörper gegen cd40
NO892589L (no) Forsinket kryssbindingsystem for fraktureringsfluider.
NO903650D0 (no) Blekeaktivator i form av granulerte partikler.
NO970895D0 (no) Fenylpeptider, fremgangsmåte for fremstilling av disse, og farmasöytiske preparater inneholdende disse peptider
PT952982E (pt) Novos inibidores da hepatite b
NO167813C (no) Fremgangsmaate for fremstilling av carboxylgruppeholdige polyamider, og anvendelse av disse som lakkbindemiddel.
EP1019500A4 (de) Neue ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
EP0596725A3 (en) Drug resistance-conferring protein, antibodies reactive therewith and utilities thereof.
NO893397L (no) Fremgangsmaate til rensing av en luftstroem for sterkt dispergerte faste partikler.
NO905200L (no) Preparater inneholdende magnetiske partikler.
BR7302483U (pt) Turbo-compressor radial com fluxo duplo
KR970053646U (ko) 색소, 약품, 식품등의 입자를 초정밀분쇄하여 강제이송시키는 펌프
NO913819D0 (no) Foringsroer og fremgangsmaate til montering av samme.
ES1027900Y (es) Sistema de archivo modular de estanterias de kioscos alineadas horizontalmente en bloques independientes.
DK163511C (da) Imidazooe1,5-aaaquinoxalinforbindelser og farmaceutiske praeparater indeholdende disse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application